Post-Genomics Blog

Forging a connection between research and clinical applications.

Working on a cure for hepatitis C

Today the Washington Post reported that two Cambridge, Mass.-based biotech firms reported impressive results from hepatitis C studies. “Vertex, developing what many experts perceive to be the most potent of the new hepatitis medicines, said yesterday that when the pill was combined in a small, early-stage study with an existing treatment, the drug cut the amount of hepatitis C virus in patients’ bodies to a minuscule fraction of its prior level in just two weeks of treatment. In past studies, dramatic drops in the amount of virus have been a prelude to cures in many patients, but it has often taken months if it happened at all.” Read the story here.

No comments yet. Be the first.

Leave a reply

You must be logged in to post a comment.

Website by Visual Flavors
Valid XHTML 1.0 Transitional
Valid CSS!
We subscribe to the HONcode principles of the HON Foundation. Click to verify.